1. Home
  2. NICE Guidance
  3. Conditions and diseases
  4. Cancer
  5. Head and neck cancers

Pembrolizumab for neoadjuvant and with radiotherapy for adjuvant treatment of newly diagnosed resectable locally advanced squamous cell head and neck cancer TS ID 12068

Awaiting development [GID-TA11599] Expected publication date: TBC

  • Project information
  • Project documents

28856-Pembrolizumab-for-Head-and-Neck-Squamous-Cell-Carcinoma-V1.0-MAY2024-NON-CONF.pdf (nihr.ac.uk)